Telomir raises $5.6M as DeJoria deepens bet on cancer drug
What's the deal? Telomir PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has secured $5.6 million in post-IPO equity financing, with billionaire entrepreneur John Paul DeJoriaDealroom has a profile for this one. Try Dealroom → increasing his investment in the company.
What's the endgame? Telomir is advancing its lead candidate, Telomir-Zn, into clinical development. The drug is targeting triple-negative breast cancer (TNBC) under an investigational new drug (IND) application cleared by the Food and Drug Administration.
Why now? The financing lands as Telomir moves from preclinical work into clinical testing — a capital-intensive stage that requires fresh funding to begin human trials.
Who's backing it? DeJoria, the co-founder of Paul MitchellDealroom has a profile for this one. Try Dealroom → and PatrónDealroom has a profile for this one. Try Dealroom →, raised his stake in the company. His continued support signals confidence in Telomir's pipeline at an early and risky phase.
The signal: A named, high-profile backer deepening his position in a small clinical-stage biotech is a vote of confidence that carries weight beyond the dollar figure. For Telomir, FDA clearance plus fresh capital clears the path toward human trials in one of oncology's hardest-to-treat cancers.
Read more: aktiencheck.de
Image credit: National Institutes of Health (NIH)
